BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity

Reuters12-20

BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity

** J.P.Morgan sees Zealand Pharma's ZELA.CO share price drop on Friday, triggered by disappointing Novo's NOVOb.CO CagriSema obesity drug trial results, as a buying opportunity

** The brokerage still sees potential in Zealand's obesity drug petrelintide in 2025, and rate the stock "overweight"

** Commenting on CagriSema results, it notes that while combo (amylin + semaglutide) was below expectations, the amylin mono headline data met expectations and showed good tolerability

** This bodes well for petrelintide, Zealand's investigational long-acting amylin analog, which showed stronger efficacy in Phase I, JPM says

** Zealand's CEO told Reuters that Cagrisema results support the company's monotherapy approach

** JPM forecasts $10 billion peak potential for petrelintide, assuming it takes 1/3 market share of GLP-1 intolerant patients

** It sees a good chance of Zealand partnering petrelintide by the end of 2025

** Zealand Pharma shares are down 15% at 0200 pm GMT, on track for worst day since March 2020

(Reporting by Vera Dvorakova)

((vera.dvorakova@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492496204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492496204","market":"us","top_or_hot":-1,"title":"BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity</title></head><body><p>** J.P.Morgan sees Zealand Pharma's <span>ZELA<a href=\"https://laohu8.com/S/02403\">.C</a>O</span> <span>share price drop on Friday, triggered by disappointing Novo's <span>NOVOb.CO</span> CagriSema obesity drug trial </span><span>results</span>, as a buying opportunity </p><p>** The brokerage still sees potential in Zealand's <span>obesity </span>drug <span>petrelintide </span>in 2025, and rate the stock \"overweight\"</p><p>** <span>Commenting on CagriSema results, it notes that while combo (amylin + semaglutide) was below expectations, the amylin mono headline data met expectations and showed good tolerability</span></p><p>   ** This bodes well for <span>petrelintide, Zealand's investigational long-acting amylin analog,</span> which showed stronger efficacy in <span>Phase I</span>, JPM says</p><p>\n<span>** Zealand's CEO </span>\n<span>told</span>\n<span> Reuters that </span>Cagrisema results <span>support the company's monotherapy approach </span></p><p>** JPM forecasts $10 billion peak potential for <span>petrelintide</span>, assuming it takes 1/3 market share of GLP-1 intolerant patients </p><p>** It sees a good chance of Zealand partnering <span>petrelintide </span>by the end of 2025</p><p><span>** Zealand Pharma shares are down 15% at 0200 pm GMT, on track for worst day since March 2020</span></p><p> (Reporting by Vera Dvorakova)</p><p> ((vera.dvorakova@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 22:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL8N3NL0VS:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity** J.P.Morgan sees Zealand Pharma's ZELA.CO share price drop on Friday, triggered by disappointing Novo's NOVOb.CO CagriSema ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL8N3NL0VS:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JPM","symbol_name":"摩根大通","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL8N3NL0VS:1","article_id":"2492496204","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492496204","pubTimestamp":1734704046,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity** J.P.Morgan sees Zealand Pharma's ZELA.CO share price drop on Friday, triggered by disappointing Novo's NOVOb.CO CagriSema obesity drug trial results, as a buying opportunity ** The brokerage still sees potential in Zealand's obesity drug petrelintide in 2025, and rate the stock \"overweight\"** Commenting on CagriSema results, it notes that while combo  was below expectations, the amylin mono headline data met expectations and showed good tolerability   ** This bodes well for petrelintide, Zealand's investigational long-acting amylin analog, which showed stronger efficacy in Phase I, JPM says. Reuters that Cagrisema results support the company's monotherapy approach ** JPM forecasts $10 billion peak potential for petrelintide, assuming it takes 1/3 market share of GLP-1 intolerant patients ** It sees a good chance of Zealand partnering petrelintide by the end of 2025** Zealand Pharma shares are down 15% at 0200","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"JPM":"摩根大通"},"translate_title":"BUZZ-JPM将Zealand Pharma股价表现不佳视为买入机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JPM":0.9},"content_text":"BUZZ-JPM sees Zealand Pharma's share underperformance as buying opportunity** J.P.Morgan sees Zealand Pharma's ZELA.CO share price drop on Friday, triggered by disappointing Novo's NOVOb.CO CagriSema obesity drug trial results, as a buying opportunity ** The brokerage still sees potential in Zealand's obesity drug petrelintide in 2025, and rate the stock \"overweight\"** Commenting on CagriSema results, it notes that while combo (amylin + semaglutide) was below expectations, the amylin mono headline data met expectations and showed good tolerability   ** This bodes well for petrelintide, Zealand's investigational long-acting amylin analog, which showed stronger efficacy in Phase I, JPM says\n** Zealand's CEO \ntold\n Reuters that Cagrisema results support the company's monotherapy approach ** JPM forecasts $10 billion peak potential for petrelintide, assuming it takes 1/3 market share of GLP-1 intolerant patients ** It sees a good chance of Zealand partnering petrelintide by the end of 2025** Zealand Pharma shares are down 15% at 0200 pm GMT, on track for worst day since March 2020 (Reporting by Vera Dvorakova) ((vera.dvorakova@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492496204"}